VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/03/16 -- Pyng Medical Corp. (TSX VENTURE: PYT), an award-winning developer of trauma and resuscitation products for emergency, combat and critical care personnel, announces the launch of FASTTactical, a new Sternal Intraosseous (IO) Infusion Device designed for civilian Emergency Medical Services (EMS), hospital critical care teams, and the military.
According to Pyng Medical CEO Mark Hodge, "Many of our civilian EMS and military customers have requested an Intraosseous Device that would both fit easily into their medical bags and also protect and keep the device sterile in the difficult environments they are required to work in. The result is FASTTactical".
FASTTactical is Pyng Medical's first Sternal IO device to feature compact rigid tube packaging that protects the device while keeping it sterile. The smaller footprint also enables the device to much more easily fit into combat and civilian medical bags than alternative IO devices.
Pyng Medical is a pioneer in Sternal Intraosseous Infusion. Their FAST1 Sternal Intraosseous Infusion System has long been accepted and successfully used for fluid management by global militaries for more than 14 years. The new FASTTactical device includes all the trusted and proven features of FAST1, but is improved in two key ways:
-- With FAST1, there are multiple parts, including a separate target patch,
whereas FASTTactical is a true all-in-one Sternal IO device with no
separate parts.
-- While FAST1 is packaged in a larger soft Tyvek pouch, FASTTactical comes
in a much smaller rigid tube package that also protects the device from
damage while keeping the device sterile.
In 2014, Pyng Medical launched their FASTResponder Sternal IO device for the use of civilian EMS and hospital critical care personnel. Aside from device color and the compact package, the FASTTactical device mirrors all characteristics and advantages of FASTResponder.
Civilian EMS and hospital critical care teams may prefer to use FASTTactical if damage to the device is a concern, such as in extreme environments or high risk transport situations.
Military and civilian teams using other intraosseous infusion products, or considering the use of intraosseous infusion devices for the first time, may be interested to know that unlike humeral or tibial IO products FASTTactical requires no batteries, drilling or separate needles.
Featuring an all-in-one design with automatic depth control built in, medical personnel are able to quickly and easily locate the sternal site, and gain consistent access without worrying about using too much pressure (cannot over-penetrate).
Additional benefits include:
-- Sternal Intraosseous Infusion is a viable alternative to traditional
intravenous (IV) access. Any fluid or medication that can be delivered
intravenously can be delivered via IO at approximately the same or
faster rate.
-- Clinical data suggest the Sternal route for IO may improve patient
outcomes as compared to other routes.
-- Patients experience less pain on both insertion and infusion with the
Sternal route when utilizing intraosseous infusion.
About Pyng Medical Corp.
Pyng Medical Corp. engineers and markets award-winning trauma and resuscitation products for front-line critical care personnel world-wide. Pyng's product portfolio includes innovative sternal intraosseous (sternal IO) pelvic stabilization and tourniquet devices specifically designed and customized for both the military and civilian markets. With growing markets in North America, Europe and Asia, Pyng develops user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.
More information about Pyng is available on SEDAR at http://www.sedar.com under the Company's profile and on its website: http://www.pyng.com.
Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbour Statement; Forward-Looking Statements:
This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
Contacts:
Pyng Medical Corp.
George Dorin
Chief Financial Officer
(604) 303-7964 x219
www.pyng.com
